As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry
Source: Streetwise Reports  (1/13/21)
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. More >

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients
Source: Streetwise Reports  (1/11/21)
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. More >

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (1/11/21)
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept? More >

Pharma Developer Outlines 2021 Clinical Program Initiatives
Source: Streetwise Reports  (1/8/21)
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. More >

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition
Source: Streetwise Reports  (1/8/21)
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. More >

Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results
Source: Streetwise Reports  (1/6/21)
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report. More >

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
Source: Streetwise Reports  (1/4/21)
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil. More >

Biopharma Appoints Adviser for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (1/4/21)
Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team. More >

Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial
Source: Streetwise Reports  (1/4/21)
Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus. More >

California Biotech Advances Two COVID-19 Products
Source: Streetwise Reports  (12/30/20)
Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report. More >

Biotech On Track for Trio of Drugs in Clinical Trials in 2021
Source: Streetwise Reports  (12/30/20)
The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report. More >

Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review
Source: Streetwise Reports  (12/29/20)
Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication. More >

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer
Source: Streetwise Reports  (12/28/20)
Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYXâ„¢ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada. More >

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher
Source: Streetwise Reports  (12/23/20)
Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder. More >

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program
Source: Streetwise Reports  (12/22/20)
Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program. More >

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
Source: Streetwise Reports  (12/21/20)
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial. More >

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties
Source: Streetwise Reports  (12/21/20)
Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties. More >

Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment
Source: Streetwise Reports  (12/17/20)
Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme. More >

Why XPhyto's PCR Test Kit Is a Game Changer for COVID-19 Testing
Source: Knox Henderson for Streetwise Reports  (12/17/20)
Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes. More >

US Specialty Pharma Makes 'Another Acquisition to Bolster Topline'
Source: Streetwise Reports  (12/16/20)
The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report. More >

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'
Source: Streetwise Reports  (12/16/20)
Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report. More >

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (12/16/20)
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators. More >

Eli Lilly's $1.04 Billion Buyout Offer Sends Prevail Therapeutics' Shares 82% Higher
Source: Streetwise Reports  (12/15/20)
Shares of Prevail Therapeutics reached a new 52-week high after the company reported it has signed a definitive agreement to be acquired by Ely Lilly in a deal valued up to $1.04 billion. More >

Alexion Pharma Shares Jump 30% on AstraZeneca's $39 Billion Buyout Offer
Source: Streetwise Reports  (12/14/20)
Shares of Alexion Pharmaceuticals reached a new 52-week high after the company reported it entered into a definitive agreement to be acquired by AstraZeneca in a combination cash and stock deal valued at US$39 billion. More >

TG Therapeutics Shares Rise 40% on Positive Topline Data from Two Phase 3 RMS Trials
Source: Streetwise Reports  (12/10/20)
Shares of TG Therapeutics reached a new 52-week high after the company released positive topline results from the Phase 3 ULTIMATE I & II Studies of ublituximab as a monotherapy for treating relapsing multiple sclerosis. More >